&nbsp;

Mar 2023

Drug

niLOtinib

Other Name(s): Tasigna®

Quick Link(s):

Jul 2025

Drug

nab-PACLitaxel

Other Name(s): Abraxane®

Quick Link(s):

Dec 2024

Drug

nelarabine

Other Name(s): Atriance®

Quick Link(s):

Apr 2024

Drug

nivolumab

Other Name(s): Opdivo®

Quick Link(s):

Dec 2025

Regimen

HYDR

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

ODB - General Benefit

hydroxyurea

Drugs Used:

hydroxyurea

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

NPAC

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

HYPERCVAD

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Curative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2022

Regimen

NLTM

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

niLUTAmide

Drugs Used:

niLUTAmide

Quick Link(s):

Regimen Monograph

Sep 2018

Regimen

NPAC(W)

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

NPAC(W)

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes

Drugs Used:

nab-PACLitaxel